







Obesity in Pregnancy

- Definition is BMI ≥ 30
- ½ of women of childbearing age are overweight or obese
- Higher prevalence
 - Low-income populations
 - Non-Hispanic black women (57 %)
 - Older maternal age
 - Higher parity
- Lower prevalence
 - Non-Hispanic Asian women (17 %)
 - Non-Hispanic White women
- Pre-pregnancy obesity in US increasing
 - 2016 US had 26% obese pre-pregnancy
 - 2019 US had 29% obese pre-pregnancy

5

Obesity in Pregnancy

- Growing challenge for obstetrical providers
- Associated with severe maternal and perinatal morbidity and mortality
 - Gestational diabetes
 - 6.3% in obese and 9.5% in morbidly obese
 - Gestational hypertension
 - Preeclampsia
 - Risk doubled with each 5-7kg/m² increase from pre-pregnancy BMI
 - Stroke
 - Obstructive sleep apnea (20 % of pregnant patients)
- Antenatal, intrapartum, and postpartum complications



Obesity in Pregnancy Antepartum complications • Higher miscarriage rates Antepartum complications Challenging to screen for anomalies Cardiac dysfunction • Higher incidence of fetal anomalies Proteinuria Cardiac Nonalcoholic fatty liver Neural tube defects • Sleep apnea • Spina bifida Stillbirth Orofacial Proportional increases Hydrocephaly DM Anorectal atresia Preeclampsia • Limb reduction defects • Challenging fetal surveillance



Obesity & Pregnancy

Adjokine
Secretion

Adjokine
Secretion

Visfatin

Leptin

Obesity & Pregnancy

Polonged Conset of Labor
Prolonged Pregnancy
Prolonged Pregnancy
Prolonged Labor
Higher Oxytocin Requirements
Higher Prevalence of Caesarean
Section



Obesity in Pregnancy

Increased fetal complications

Macrosomia

Unexplained stillbirth

Increase in prolonged pregnancy

More labor inductions

NICU admission

Neonatal death

More twins

Higher NIPT test failures (decreased fetal fraction)

Higher miscarriage rates

4-fold increase in miscarriage with fertility treatment

Obesity in Pregnancy 2020-2025 Dietary Guidelines for Americans Recommends people achieve healthy weight before pregnancy 40% of women are at a healthy weight in 2020 Weight loss before pregnancy is recommended for obese women Supported by FIGO and ACOG Improve pregnancy outcomes Weight loss postpartum is also recommended Minimize cumulative weight gain Minimize complications in subsequent pregnancies



Diet Quality

- Obese women typically have low diet quality
 - Nutritionally compromised before pregnancy
 - Consume 10% more empty calories than normal weight women
- Interventions are needed to improve diet quality pre-pregnancy
 - Beneficial to placenta and fetus
 - Better obstetrical outcomes
 - Improved perinatal survival
 - Decreased risk of preterm birth, HTN, and DM
 - Better long-term health
- Can use FIGO Nutrition Checklist to evaluate nutritional adequacy
 - Pregnant women fall short of recommendations
 - Vegetables, fruits, whole grains, dairy, and seafood
 - Overconsume sodium, saturated fat, and added sugars

15

Preconception Dieting

- Severe dieting around conception (within 3 months)
 - Not recommended
 - Severe fat restrictions
 - Intermittent fasting
 - Cleanses and detox
 - Nutrient deficiencies
 - Adverse pregnancy outcomes
- Low carbohydrate diets not recommended before conception
 - · Limits intake of folic acid
 - 30% increase in neural tube defects
 - High in saturated fat and may increase fetal macrosomia
- Vegetarian diets
 - May be low in folate, B12, iron, and zinc
 - · Lowers risk of excessive weight gain
 - Lowers risk of gestational DM


Bariatric Surgery

- Bariatric surgery before pregnancy
 - Reduced obesity related comorbidities and complications
 - Improves pregnancy outcomes
- Increased risk
 - Fetal growth restriction and SGA infants
 - Malnutrition
 - Preterm birth
 - Congenital abnormalities
 - Perinatal mortality
- Postpone pregnancy until a stable weight is achieved
 - 1 year after sleeve gastrectomy
 - 1 year after Roux-en-Y bypass
 - 2 years after adjustable gastric band procedure


17


Weight Loss in Pregnancy

- Weight loss during pregnancy
 - Lower risk of fetal macrosomia and large infants
 - Lower risk of cesarean delivery
 - Higher risk of low birth weight
 - No benefits to reduce preeclampsia or DM
 - · May increase preterm delivery
 - Increase ketones and thus adverse events
 - Stillbirth
 - Weight gain of 5-9 kg during pregnancy recommended









Diabetes in Pregnancy AJOG 2000 – 2019 Pregestational DM was associated with severe maternal morbidity Cesarean delivery Hypertensive disorders of pregnancy Preterm birth Stillbirth Macrosomia Cardiac and non-cardiac congenital defects Shoulder dystocia Goal of hgb a1c 6.5 at conception Conclusion Pregestational DM increasing due to quadrupling of prevalence of Type 2 DM Prevalence of chronic DM complications doubled Optimizing diabetes care in childbearing age is a major public health importance

23





Gestational Diabetes

• Adverse pregnancy outcomes higher than general population

• 95% increase in cost per pregnancy (over \$5 billion internationally annually)

• GDM treatment clearly reduces adverse pregnancy outcomes

• Early screening and treatment before 20 weeks is controversial. Expert opinion recommendation.

• Impact on long-term offspring outcomes remains to be determined

• Multiple criteria for diagnosing GDM are acceptable in US

• WHO has adopted one step approach

• Higher prevalence of GDM


• Higher costs of providing treatment


• Lack of data showing benefit


• ACOG continues to recommend two step approach

• Additional increased risk with only elevated fasting on 3 hour

• Perinatal and long-term offspring outcomes are directly related to glycemic control during pregnancy











• Treatment • Nutritional therapy and exercise (GDMA1) • Decreased risk of macrosomia • Decreased leonatal adiposity • Increased likelihood to achieve postpartum weight goals • 30 grams carb breakfast then 45-60 grams at lunch and dinner • 2-3 snacks • Bedtime snack helps counteract ketosis from overnight fasting • 2 meal replacements per day showed initial good results • Medication (GDMA2) • Women who need medication have more adverse outcomes (higher glucose levels)

31



Gestational Diabetes Gestational diabetes treatment Oral agents Glyburide Significant and highly variable transplacental transfer Similar glycemic control as insulin Recent data concerns about increased risk of macrosomia and neonatal hypoglycemia Long term safety data are lacking Promotes weight gain No studies on safety in pregnancy and not recommended GLP-1 receptor agonists (GLP-1RA) Sodium glucose-cotransporter 2 inhibitors (SGLT-2 inhibitors) Stop 3 months prior to conception








Hypertension in Pregnancy


How does HTN impact the morbidity and mortality of pregnancy?


What is the optimal care of hypertensive disease before and during pregnancy?















ACOG recommendation level A Any high-risk factor or > 1 moderate risk factor start 81 mg ASA daily between 12-16 weeks ASA modulates platelet function Modulates inflammation Reduces placental dysfunction ACOG recommendation level A Gestational hypertension or preeclampsia WITHOUT severe features • Deliver by 37 0/7 weeks · Treat with magnesium in labor if severe range BP ACOG recommendations level B · Gestational hypertension or preeclampsia WITH severe features • Deliver by 34 0/7 weeks · Treat with magnesium in labor Follow management guidelines for severe preeclampsia remote from term • Severe hypertension 160/110 · Confirmed and persistent at 15 minutes • Treat within 30-60 minutes




Hypertension in Pregnancy/AJOG Special Report/ Sept 2023 Care Plan for Individuals at Risk for Preed Patients at moderate to high risk for preeclampsia · Safe, cost-effective, minimally intrusive Ideal management is prevention Treat preconceptually • Treat HTN over 140/90 Decrease risk and severity of preeclampsia · Reduced morbidity for infant Assess risk factors Identify patients at risk COVID-19 in pregnancy Vaccinate to prevent Biochemical tests in development to help with this · Social determinants of health screening • Independent risk for preeclampsia Roberts, James M et al. "Care Plan for Individuals at Risk for Preeclampsia: Shared Approach to Education, Strategies for Prevention, Surveillance, and Follow-Up." American journal of obstetrics and gynecology. 229.3 (2023): 193-213. Web











Health Care Provider Guidelines for Care of Individuals at Risk for <i>Preeclampsia</i>	
The Care Plan for Intiliniduals at Risk for Prevalents is for pregnant persons considered at risk for pre-eclampsis at least sufficient to recommend prophylactic aspirin therapy during pregnancy. The following chacklest summarizes the Care Plan's recommendations for health care providers:	
Antenatal Care	
Identify individual as at-risk for presclampsis Evaluate individuals with prior presclampsis for post-traumatic stress disorder and provide resources and/or refresh for counseling if necessary Customize care plant recommendations relative to accoult determinants of health and individual needs Manage on exasting disorderly that increases the risk for presclampsis OVID-19 vaccination or booster is secommended for individual who are not fully veccinated. Recommand self-motivating of blood pressure at home every 2 weeks until 20 weeks, then weekly until birth or more frequently if indicated. Provide self-motivating blood pressure at home every 2 weeks until 20 weeks to appropriately-stood, vidented out?	
Pharmscologic recommendations Initiate low-dose apprin therapy (81 mg/day) between 12 and 28 weeks: gestation (optimally before 15 weeks weeks. There is reasonable date to support that explini doses s 100mg may be acceptable alternatives to alling.) Controval low-dose apprint therapy send by the optimization of the optimization approach to the optimization and guidance that will support adherence to low-dose apprint therapy. For presons with obscinic hypertension administer enthypertension for the response.	
Behavioral recommendations	
Roberts, James M et al. "Care Plan for Individuals at Risk for Preeclampsia: Shared Approach to Education, Strategies for Probstetrics and gynecology. 229.3 (2023): 193–213. Web	evention, Surveillance, and Follow-Up." American journal of














Angiogenic Factors as Biomarkers for Preeclampsia with Severe Features
NEJM Nov 2022
Angiogenic placental growth factors

Tyrosine kinase 1 (sFlt-1)
Placental growth factor (PIGF)

sFlt-1/PIGF ratio of ≤ 38
Hospitalized patients 23-35 weeks
Rule out preeclampsia in women with suspected pre-eclampsia
No preeclampsia in subsequent 1 week
NPV of 99.3%
Sensitivity (LOW) of 80.0%
ACOG does not support use

Angiogenic Factors as Biomarkers for Preeclampsia with Severe Features

- NEJM Nov 2022
- Placental growth factor (PIGF) <100 pg/ml
 - Helps rule out preeclampsia in women with suspected preeclampsia
 - Before 35 weeks
 - No preeclampsia requiring delivery in subsequent 2 weeks
 - Sensitivity of 96%
 - NPV of 98%
- ACOG does not support use
- No test to "RULE-IN" preeclampsia or predict development

56

